Company’s 36-month beta value is 2.74.Analysts have differing opinions on the stock, with 11 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SYRE is 51.32M, and currently, short sellers hold a 23.56% ratio of that floaft. The average trading volume of SYRE on June 13, 2025 was 615.75K shares.
SYRE) stock’s latest price update
The stock of Spyre Therapeutics Inc (NASDAQ: SYRE) has decreased by -1.61 when compared to last closing price of 18.00.Despite this, the company has seen a gain of 6.56% in its stock price over the last five trading days. prnewswire.com reported 2025-06-06 that WALTHAM, Mass., June 6, 2025 /PRNewswire/ — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 50,200 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”).
SYRE’s Market Performance
Spyre Therapeutics Inc (SYRE) has experienced a 6.56% rise in stock performance for the past week, with a 20.07% rise in the past month, and a -1.77% drop in the past quarter. The volatility ratio for the week is 4.84%, and the volatility levels for the past 30 days are at 3.15% for SYRE. The simple moving average for the last 20 days is 10.94% for SYRE’s stock, with a simple moving average of -22.74% for the last 200 days.
Analysts’ Opinion of SYRE
Many brokerage firms have already submitted their reports for SYRE stocks, with Leerink Partners repeating the rating for SYRE by listing it as a “Outperform.” The predicted price for SYRE in the upcoming period, according to Leerink Partners is $45 based on the research report published on April 08, 2025 of the current year 2025.
Wolfe Research, on the other hand, stated in their research note that they expect to see SYRE reach a price target of $27. The rating they have provided for SYRE stocks is “Outperform” according to the report published on March 18th, 2025.
Wedbush gave a rating of “Outperform” to SYRE, setting the target price at $45 in the report published on September 04th of the previous year.
SYRE Trading at 21.25% from the 50-Day Moving Average
After a stumble in the market that brought SYRE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.01% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SYRE starting from Albers Jeffrey W., who sale 6,700 shares at the price of $36.76 back on Nov 06 ’24. After this action, Albers Jeffrey W. now owns 27,360 shares of Spyre Therapeutics Inc, valued at $246,313 using the latest closing price.
Albers Jeffrey W., the Director of Spyre Therapeutics Inc, sale 300 shares at $36.43 during a trade that took place back on Oct 25 ’24, which means that Albers Jeffrey W. is holding 34,060 shares at $10,929 based on the most recent closing price.
Stock Fundamentals for SYRE
The total capital return value is set at -0.43. Equity return is now at value -50.47, with -30.31 for asset returns.
Currently, EBITDA for the company is -207.97 million with net debt to EBITDA at 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.06.
Conclusion
In a nutshell, Spyre Therapeutics Inc (SYRE) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
